Fridays vs MEDVi vs Yucca Health (2026)

On tirzepatide, the order is Yucca Health↗ ($258) → Fridays ($359) → MEDVi↗ ($399) — gaps of $101 and then $40 a month, a $1,692 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

§ Each record, condensed

The three records, one screen

Yucca Health: the record, condensed

Yucca Health’s tirzepatide program bills $258 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Yucca Health is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #2 of 17 verified programs, with the floor $43/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $191 a month. A year at this figure: $3,096 monthly-billed.

Yucca Health’s semaglutide program bills $146 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $146 is the whole subscription, which makes Yucca Health unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #2 of 20 in the verified semaglutide index — $13/month above the floor (Oak Longevity, $133) — and sits $203 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $1,752.

Operationally at Yucca Health: shipping included; commitment 6-month term; cancellation 6-month term applies; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Yucca Health page · visit Yucca Health ↗

Fridays: the record, condensed

Start with the load-bearing figure: $359 a month, all-in, is what Fridays charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $359 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #13 of 17 in the verified tirzepatide index — $144/month above the floor (NexLife, $215) — and sits $90 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $4,308.

Fridays’s semaglutide program bills $175 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Fridays is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $175 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #7 of 20 verified programs, with the floor $42/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $174 a month. A year at this figure: $2,100 monthly-billed.

Operationally at Fridays: shipping included; commitment annual plan for lowest rate; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Fridays page · visit Fridays ↗

MEDVi: the record, condensed

On tirzepatide, the number that matters at MEDVi is $399 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at MEDVi is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #14 of 17 in the verified tirzepatide index — $184/month above the floor (NexLife, $215) — and sits $50 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $4,788.

Start with the load-bearing figure: $299 a month, all-in, is what MEDVi charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #18 of 20 verified programs, with the floor $166/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $50 a month. A year at this figure: $3,588 monthly-billed.

Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗

§ The three-way read

Prices, gaps, and what sits inside them

Yucca Health holds the low ground at $258 — dose-flat, so that figure is a ceiling with no membership attached. Fridays follows at $359 (+$101/mo, $1,212/yr). MEDVi tops the trio at $399 (+$141/mo over the leader, $1,692/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles nothing: Yucca Health $146 → Fridays $175 → MEDVi $299 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

§ Category winners among the three

Who wins what

Cheapest month-to-month: Yucca Health ($258); cheapest 12-month path: Yucca Health ($3,096); cheapest semaglutide of the three: Yucca Health ($146).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: Yucca Health vs Fridays · Yucca Health vs MEDVi · Fridays vs MEDVi.

§ Structure, three ways

Everything besides the three prices

Memberships: Yucca Health none; Fridays none; MEDVi none. Structures: Yucca Health dose-flat; Fridays dose-flat; MEDVi dose-flat. Pharmacies: Yucca Health not named; Fridays not named; MEDVi not named. States: Yucca Health — not published; Fridays — not published; MEDVi — priced differently in CA/NC on some plans. Exit terms: Yucca Health — 6-month term applies; Fridays — not published; MEDVi — 12-month plan applies to lowest rate.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: Yucca Health source-verified (2026-08-05); Fridays third-party reported (2026-08-05); MEDVi source-verified (2026-08-05).

The trio on semaglutide, across time

3 mo: Yucca Health $438 vs Fridays $525 vs MEDVi $897 6 mo: Yucca Health $876 vs Fridays $1,050 vs MEDVi $1,794 12 mo: Yucca Health $1,752 vs Fridays $2,100 vs MEDVi $3,588 — monthly-billed totals; prepaid paths where published appear on each provider page.

§ Twelve and twenty-four months

The trio, annualized

Yucca Health: $3,096/yr monthly-billed; Fridays: $4,308/yr monthly-billed; MEDVi: $4,788/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $3,384 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

A three-way choice is really two eliminations, so run them in order. Eliminate MEDVi first unless it names its edge: at $399 it carries a $141/month premium over the floor of this trio — $1,692 a year, about 6.6 extra months of therapy at Yucca Health’s rate — and a premium that size must point at a specific line in its record (its particular program design) or it is decoration. Then interrogate Fridays’s middle ground: nothing structural — its case is purely situational; if that specific thing is on your personal ledger, the $101/month over the floor can be rational — if not, the middle is where budgets go to leak. What survives is Yucca Health at $258, which wins by default rather than by argument — exactly how a price index should crown things — subject to the two checks no ranking can run for you: your state at intake, and your prescriber on the medication itself.

The same trio on best published rate: Yucca Health $258 → Fridays $359 → MEDVi $399 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — Yucca Health $774, Fridays $1,077, MEDVi $1,197; 6 months — Yucca Health $1,548, Fridays $2,154, MEDVi $2,394. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

The record-quality read, scored on the five checkable disclosures this index tracks (maintenance price, named pharmacy, published states, published cancellation terms, source-verified capture): Yucca Health 4/5, Fridays 3/5, MEDVi 4/5. Yucca Health discloses the most and Fridays the least, and in this market disclosure predicts disclosure — the axis where a program goes quiet is reliably where its checkout surprises live. The three match on every disclosure axis, which is rare and worth noting in their favor collectively. Scores recompute from the public records like everything else here.

Read as a decision: start from Yucca Health and make the other two argue upward. Fridays’s case is its structure; MEDVi’s case must be worth $1,692 a year in named features — the honest unit being months of medication (6.6 of them at the floor rate). The pairwise pages above hold each argument in full, and the calculator holds your version of it.